News 2024-12-23
Porton Pharma Solutions and Dragon Sail Pharmaceutical Form Strategic Partnership
On December 20, 2024, Porton Pharma Solutions Ltd. (hereinafter
referred to as “Porton Pharma Solutions” or “Porton”) and Dragon Sail
Pharmaceutical (Shanghai) Co., Ltd. (a subsidiary of Guilin Sanjin, hereinafter
referred to as “Dragon Sail Pharmaceutical”) formally signed a strategic
cooperation agreement in Guilin, southern of China. This collaboration aims to
carry out in-depth cooperation in the research, development, production, and
supply chain integration of antibody-drug conjugates (ADC). Attendees at the
signing ceremony included Mr. Ju Nianfeng, Chairman and General Manager of
Porton Pharma Solutions, Mr. Zou Xun, Chairman of Guilin Sanjin, and Mr. Tan
Kai, General Manager of Dragon Sail Pharmaceutical.
As a leading end-to-end integrated CDMO company in the
industry, Porton Pharma Solutions boasts globally advanced technology platforms
and extensive project delivery experience in small molecules, peptides and
oligonucleotides, ADCs (including antibodies, payload-linkers, conjugation, and
drug product filling), and Advanced Therapy Medicinal Products. Dragon Sail
Pharmaceutical, on the other hand, has unique advantages in the development of
biological drugs such as monoclonal antibodies, bispecific antibodies, and
fusion proteins. By integrating resources, technical capabilities, and
production capacities in the ADC drug field, the two companies will leverage
supply chain resource sharing and complementary strengths to form a close
cooperation mechanism. This partnership aims to establish a comprehensive
one-stop service platform for ADC drugs, encompassing the entire process from
bulk drug substances to finished products, from early-stage development to
commercial production. By doing so, the collaboration seeks to shorten ADC drug
development timelines, enhance service and delivery capabilities, and improve
market competitiveness, providing global customers with more efficient and
reliable one-stop CMC solutions for ADC drugs.
Mr. Oliver (Nianfeng) Ju
At the ceremony, Mr. Oliver (Nianfeng) Ju, Chairman and CEO
of Porton Pharma Solutions, stated, “This strategic cooperation is of great
significance, not only helping enhance the competitiveness of both businesses
but also bringing more innovative achievements to the pharmaceutical industry.
Moving forward, Porton will continue to leverage its ADC drug platform
advantages, deepen cooperation with Dragon Sail Pharmaceutical, and work
together to contribute to the advancement of the global pharmaceutical
industry.”
Mr. Zou Xun
At the ceremony, Mr. Zou Xun, Chairman of Guilin Sanjin,
remarked, “This partnership goes beyond deep business integration between the
two companies; it is also aimed at promoting the development of ADC drugs.”
Looking ahead, Porton Pharma Solutions and Dragon Sail
Pharmaceutical will take Shanghai Waigaoqiao (Porton) and Shanghai Lingang
(White Sail) as their bases to uphold the shared vision of enabling the
public’s early access to good medicines together. They will strive to
create a globally impactful and sustainable pharmaceutical ecosystem through
technological innovation and business model innovation. By completing resource
integration and improving overall efficiency, the two companies aim to jointly
promote the rapid and healthy development of the global ADC pharmaceutical
industry.
Founded in 2005, Porton Pharma
Solutions Ltd. is an internationally recognized pharmaceutical contract
development and manufacturing organization (CDMO) in enabling our global
clients to optimize drug development and manufacturing. We provide customer development
and manufacturing services for small molecules, TIDES, biologics and conjugates
(ADCs, AOCs, PDCs, RDCs, etc.) from pre-clinical to commercialization stages.
As of June 30, 2024, we have a proven record for the delivery of more than 3500
projects and established cooperation with more than 1000 global clients. With
our 4300+ skilled employees working across 20+ sites around the globe, Porton
is committed to becoming the most open, innovative and reliable pharmaceutical
service platform in the world and enabling the public’s early access to good
medicines.
Find more about us: www.portonpharma.com
business@portonpharma.com
[Porton Biologics and
Conjugates CDMO Platform]
Porton Biologics and Conjugates CDMO Platform operates multiple R&D centers
and GMP manufacturing sites in Shanghai, China, and New Jersey, USA
respectively. It provides integrated, end-to-end CDMO solutions for global
pharmaceutical companies and drug development institutions, covering all stages
from preclinical development to commercial launch for biologics and conjugates.
The platform offers a comprehensive range of services, including Payload-Linker
preparation, conjugate drug developability research, cell line construction,
upstream and downstream process development, conjugation process development,
formulation development, analytical method development, GMP manufacturing of
drug substance (DS) and drug product (DP) for biologics and conjugates,
stability studies, clinical trial material production, and CMC services such as
pharmaceutical documentation support for regulatory filings.
Find more about us:
www.portonpharma.com/en/biologics
business@portonpharma.com
Guilin Sanjin
Pharmaceutical Co., Ltd., the core enterprise of Sanjin Group, specializes in
the R&D and production of traditional Chinese medicine (TCM) and natural
medicines. As one of the earliest manufacturers of modern TCM formulations in
China, Guilin Sanjin has been committed to reform and innovation since 1985.
Leveraging technological advancement and scientific management, it has
transformed from a small TCM workshop into a nationally renowned modern TCM
enterprise, ranking among the top 50 in China's TCM industry.
The company
has received numerous honors, including the National Outstanding Contribution
Award for Enterprise Management, National Excellent Enterprise for Ideological
and Political Work, National Civilized Unit, National Outstanding Enterprise in
the TCM Industry, National Technology Innovation Demonstration Enterprise,
National Intellectual Property Demonstration Enterprise, National Quality
Benchmark, China Quality Award Nomination, and the "China Time-Honored
Brand" designation.
Dragon Sail
Pharmaceutical Co., Ltd. is a high-tech enterprise focusing on antibody drug
CDMO services, and it is dedicated to providing one-stop services for partners
from sequence to IND, clinical sample production to BLA and commercial
production of antibody drugs.
Dragon Sail
Pharmaceutical has built China’s first cross-contamination-free antibody
production facility in Lin-gang Special Area of China (Shanghai) Pilot Free
Trade Zone, with a total investment of RMB 690 million. The facility boasts a
maximum drug substance production capacity of 12,000L, adheres to cGMP
standards for China, the US, and Europe, and has passed EU QP audits.
Its unique
NONCROS® cross-contamination-free antibody production platform supports
compliant multi-product production lines with high operational efficiency and
significant cost advantages. The company has established partnerships with over
100 biopharmaceutical companies worldwide, successfully delivering over 50
antibody protein projects, advancing 3 BLA projects, and is expected to achieve
commercial project filings by the end of 2025.
Others
MoreNews 2025-01-14
Successful GMP Drug Product Delivery by Porton Biologics and Conjugates Platform
Recently, the Porton Biologics and Conjugates Platform successfully completed the GMP contract manufacturing of three batches of sterile drug products for a client at our R&D and production facility in Pudong, Shanghai. This milestone marks a significant step forward for our Biologics and Conjugates CDMO platform—a testament to our unwavering commitment to quality and reliability.
News 2025-01-03
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
Porton Pharma Solutions Ltd. (hereinafter “Porton”) is glad to announce that it scored 44 (out of 100) in the 2024 S&P Global Corporate Sustainability Assessment reflecting an improvement of 6 points over the previous assessment, where scores in all the three dimensions getting improved. (CSA Score as of 27/11/2024).